Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 4Unknown 2Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Hepatocellular 9Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 7Stomach Neoplasms 4Recurrence 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Lung Neoplasms 3Colorectal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Multiple Pulmonary Nodules 1Mid-low Rectal Cancer 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cisplatin 22Radiotherapy, Intensity-Modulated 12Fluorouracil 9Gemcitabine 7Docetaxel 7Cetuximab 5Capecitabine 5pembrolizumab 4nimotuzumab 3nedaplatin 3Radiotherapy 3Radiation 3Carboplatin 3toripalimab 2spartalizumab 2camrelizumab 2anlotinib 2Quality of Life 2Protons 2Paclitaxel 2Nivolumab 2Dexamethasone 2Chemoradiotherapy 2tislelizumab 1raltitrexed 1penpulimab 1icotinib 1fosaprepitant 1famitinib 1endostar protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Nasopharyngeal Carcinoma × tislelizumab × Clear all
NCT04215978 2025-10-03

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
204 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡